Royalty Report: Drugs, Cancer, Pharmaceuticals – Collection: 275366

$100.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 5

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 5

Primary Industries

  • Drugs
  • Cancer
  • Pharmaceuticals
  • Disease

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 275366

License Grant
Licensor of Denmark grants Licensor of Switzerland. the remaining rights to ofatumumab.

The product, Ofatumumab, is being commercialized by Licensee.

License Property
The Product, ofatumumab, is marketed as Arzerra for certain indications of chronic lymphocytic leukemia (CLL).

Ofatumumab is a human IgG1k mAb that targets an epitope on the CD20 molecule, which is found on the surface of B-cells, the type of cell which is believed to trigger the inflammatory process that leads to multiple sclerosis (MS).

Field of Use
Ofatumumab for the treatment of cancer and also for non-cancer treatments.  Ofatumumab, previously approved for certain CLL indications, is in pivotal Phase III testing by Licensee for the treatment of RMS, with the Phase III ASCLEPIOS I and II studies.

IPSCIO Record ID: 46309

License Grant
The Company entered into an Exclusive License Agreement with Licensee for U.S. and Canadian rights to the Company's bendamustine hydrochloride (HCl) rapid infusion product for treatment of patients with chronic lymphocytic leukemia and patients with indolent B-cell non-Hodgkin lymphoma. This license agreement is for BENDEKAâ„¢.
License Property
BENDEKA was granted Orphan Drug Designations for both CLL and indolent B-cell NHL for treatment of patients with chronic lymphocytic leukemia, ('CLL') and patients with non-Hodgkin's lymphoma ('NHL').
Field of Use
BENDEKA™ is a bendamustine hydrochloride injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.

IPSCIO Record ID: 271809

License Grant
The Licensor of Denmark grants an exclusive development, manufacturing and commercialization is a global license for daratumumab.
License Property
Daratumumab, marketed as DARZALEX, is a human IgG1k monoclonal antibody, or mAb, that binds with high affinity to the CD38 molecule, which is highly expressed on the surface of MM cells.
Field of Use
Daratumumab is for the Treatment of Multiple Myeloma.
Multiple myeloma, also known as plasma cell myeloma, is a cancer of plasma cells, a type of white blood cell which normally produces antibodies.

IPSCIO Record ID: 26608

License Grant
Both parties wish for Licensee to have all rights it may require for the purpose of developing, commercialising and otherwise exploiting the Product, world-wide, to which end Licensor will grant to Licensee all necessary licences as of December 6, 2006. Licensee has entered into an agreement to in-license from, and co-development with licensor, IP for acadesine in the treatment of B-cell chronic lymphocytic leukaemia (B-CLL).
License Property
Licensor believes that acadesine may prove a more specific therapy for B-CLL than current treatments that are generally toxic to both B- and T-cells resulting in a range of side effects including an increased risk of infection. Acade-sine was well tolerated in clinical studies in an unrelated indication.

Acadesine is a nucleoside analogue with a novel mechanism of action, which unlike most existing treatments for B-CLL, has been shown, in an ex vivo study, to target B-cells selectively, while minimising toxicity to T-cells. The company believes that it may have reduced development risk, since it was well tolerated when previously studied for an unrelated indication. A proof-of-concept Phase I study in B-CLL, which is planned to be conducted in 2007, will investigate B-cell selectivity in patients with cancer.

Field of Use
Field of Use means any and all areas of human use of the Product.

IPSCIO Record ID: 190857

License Grant
Licensor announced that the Centers for Medicare and Medicaid Services established a unique, product-specific billing code, J-code (J9034), for Bendeka. The J-code became effective on January 1, 2017. The new J-code provides reimbursement coding clarity to outpatient facilities and physicians that administer Bendeka, a chemotherapy drug used to treat chronic lymphocytic leukemia and non-Hodgkin lymphoma.
License Property
The original license agreement is for BENDEKA™, (bendamustine hydrochloride) injection, a liquid, low-volume (50 mL) and short-time 10-minute infusion formulation of bendamustine for the treatment of patients with chronic lymphocytic leukemia (“CLL”) and for the treatment of patients with indolent B-cell non-Hodgkin lymphoma (“NHL”) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen.
Field of Use
This agreement pertains to the drug industry.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.